Entrada Therapeutics, Inc. (TRDA)
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailments. The company leverages its proprietary EEV platform to cultivate a rich pipeline of therapeutic programs, integrating oligonucleotide, antibody, and enzyme-based approaches. Its foremost product candidate, ENTR-601-44, is currently undergoing preclinical assessment for its potential in addressing both Duchenne muscular dystrophy and myotonic dystrophy type 1. Furthermore, Entrada is actively developing EEV-PMO-CAG, also targeting myotonic dystrophy type 1. Incorporated in 2016, the firm was formerly known as CycloPorters, Inc., before officially changing its name to Entrada Therapeutics, Inc. in October 2017. The company maintains its corporate headquarters in Boston, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Entrada Therapeutics, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Phase 2Not yet recruiting
Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
ENTR-601-44, ENTR-601-45
Duchenne Muscular Dystrophy (DMD)
NCT07682129Enrollment80StartAug 2026est.Primary CompletionMar 2032est.CompletionMar 2032est. - Phase 1/2Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44
ENTR-601-44, ENTR-601-44 - matching placebo
Duchenne Muscular Dystrophy (DMD)
NCT07037862Enrollment24StartJun 2025Primary CompletionMar 2029est.CompletionMar 2029est. - Phase 1/2Recruiting
A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45
ENTR-601-45, ENTR-601-45 - matching placebo
Duchenne Muscular Dystrophy (DMD)
NCT07038824Enrollment24StartAug 2025Primary CompletionMar 2029est.CompletionMar 2029est. - ObservationalSuspended
Natural History Study of MNGIE
Non-interventional
Mitochondrial Neurogastrointestinal Encephalomyopathy
NCT04245917Enrollment60StartAug 2020Primary CompletionFeb 2025est.CompletionFeb 2026est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Phase 2 | Not yet recruiting | ENTR-601-44, ENTR-601-45 | NCT07682129 |
| Phase 1/2 | Recruiting | ENTR-601-44, ENTR-601-44 - matching placebo | NCT07037862 |
| Phase 1/2 | Recruiting | ENTR-601-45, ENTR-601-45 - matching placebo | NCT07038824 |
| Observational | Suspended | Non-interventional | NCT04245917 |